There are currently 117 active clinical trials seeking participants for Schizophrenia research studies. The states with the highest number of trials for Autism participants are California, Florida, Texas and New York.
Virtual Reality Training for Social Skills in Schizophrenia - Comparison With Cognitive Training
NCT04005794
Recruiting
Social impairments are core features of schizophrenia that lead to poor outcome. Social skills and competence improve quality of life and protect against stress-related exacerbation of symptoms, while supporting resilience, interpersonal interactions, and social affiliation. To improve outcome, it is necessary to remediate social deficits. Existing psychosocial interventions are moderately effective but the effort-intensive nature (high burden), low adherence, and weak transfer of skills to ever... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
12/07/2022
Locations: Vanderbilt University, Nashville, Tennessee
Conditions: Schizophrenia, Schizo Affective Disorder, Social Skills
Register for Updates
A Single-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
NCT05635266
Recruiting
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and preventative methods for specific and complex conditions.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
11/22/2022
Locations: Sanguine Biosciences, Waltham, Massachusetts
Conditions: Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
Register for Updates
Cigarette Smoking in Smokers With and Without Schizophrenia
NCT04001114
Recruiting
Higher rates and severity of tobacco dependence in people with schizophrenia, as compared with the general population, contribute to the lower life expectancy seen in this population. Dependent tobacco smoking is controlled by how different aspects of cigarette smoking are perceived. There is evidence suggesting that people with schizophrenia differ in how they perceive cigarette smoking, which, if confirmed, would have implications for tailoring treatment interventions for smoking cessation in... Read More
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
10/07/2022
Locations: Maryland Psychiatric Research Center, Catonsville, Maryland
Conditions: Tobacco Dependence, Schizophrenia
Register for Updates
Real-time fMRI Neurofeedback in Patients With Schizophrenia and Auditory Hallucinations
NCT05299749
Recruiting
Neurofeedback intervention aimed to regulate the superior temporal gyrus (STG) activation and default mode network (DMN) connectivity as well as to reduce the auditory hallucinations (AH) schizophrenia patients with medication resistant AH.
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
09/20/2022
Locations: Boston VA Healthcare System, Brockton, Brockton, Massachusetts
Conditions: Schizophrenia, Auditory Hallucination, Treatment-resistant Schizophrenia
Register for Updates
Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia
NCT03781115
Recruiting
Schizophrenia is a severe psychotic illness of unknown cause that affects 1% of the population worldwide. Currently, there is no diagnostic test for schizophrenia. Instead, the diagnosis is typically established through a psychiatric interview of the patient, who is evaluated against a set of established criteria of signs and symptoms. It can take many months to years to establish a diagnosis of schizophrenia and achieve an appropriate treatment regimen to attain resolution of the patient's symp... Read More
Gender:
All
Ages:
Between 18 years and 40 years
Trial Updated:
02/23/2022
Locations: Banner Alzheimer's Institute, Phoenix, Arizona +1 locations
Conditions: Schizophrenia
Register for Updates
Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®
NCT01908192
Recruiting
The purpose of this study is to determine if NaBen® is a safe and effective add-on treatment for schizophrenia in adolescents.
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
09/10/2021
Locations: Harmonex Neuroscience Research, Dothan, Alabama +22 locations
Conditions: Schizophrenia
Register for Updates
Study to Evaluate Safety & Efficacy of NaBen® as Add-on Treatment for Schizophrenia in Adults
NCT02261519
Recruiting
The proposed Phase IIb/III study is designed to evaluate the safety and efficacy of NaBen® in improving the symptoms of schizophrenia in adults. NaBen® is granted Breakthrough Therapy Designation by US FDA as add-on treatment for schizophrenia. The trial is designed as a multi-center, prospective, randomized, placebo-controlled, in which adult subjects with schizophrenia will be enrolled. The study will include four parts: a 2 week Screening part, a 4 week run-in part, an 8 week double-blind tre... Read More
Gender:
All
Ages:
Between 18 years and 45 years
Trial Updated:
09/10/2021
Locations: For additional information regarding investigative sites for this trial, contact SyneuRx International Corp., Pasadena, California
Conditions: Schizophrenia
Register for Updates
Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia
NCT04519099
Recruiting
To evaluate the efficacy and safety of cariprazine at a target dose of 4.5 mg/d compared with placebo in prevention of relapse in patients with schizophrenia To evaluate the efficacy and safety of cariprazine at a target dose of 3.0 mg/d compared with placebo in prevention of relapse in patients with schizophrenia who were initially stabilized on a target dose of 4.5 mg/d
Gender:
All
Ages:
Between 18 years and 64 years
Trial Updated:
08/17/2020
Locations: Pillar Clinical Research, Bentonville, Arkansas +120 locations
Conditions: Schizophrenia
Register for Updates
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
NCT03495024
Recruiting
To test the feasibility of studying effects of smoking cessation with varenicline on antipsychotic drug-induced neurological side effects, we propose a 12 week pilot study of smoking cessation treatment with varenicline in 10 schizophrenia or schizoaffective disorder patients who are actively smoking and have pre-existing TD while receiving stable doses of antipsychotics. Subjects will be followed after a 2 week baseline period to assess changes in smoking status and neurological symptoms using... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/20/2019
Locations: Corporal Michael J Crescenz VA Medical Center, Philadelphia, Pennsylvania
Conditions: Schizophrenia, Schizoaffective Disorder, Tobacco Smoking, Tardive Dyskinesia, Parkinsonism
Register for Updates